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The endothelium of the blood vessel wall forms a barrier for 
blood solutes and for leukocytes. The entry of molecules and 
cells of the immune system into inflamed tissue is mainly reg-
ulated via endothelial junctions. Vascular endothelial (VE)–
cadherin is a central component of these junctions, and it is 
generally considered one of the major adhesive mechanisms 
that controls the stability and barrier function of the endo-
thelium (Dejana and Vestweber, 2013). Antibodies against 
VE-cadherin can destabilize endothelial junctions in vitro 
and in vivo (Breviario et al., 1995; Gotsch et al., 1997; Corada 
et al., 1999). In agreement with this, enhancing the adhesive 
function of VE-cadherin by directly fusing it to α-catenin 
blocks the induction of vascular permeability in the skin of 
the respective knock-in mice and strongly reduces leukocyte 
extravasation in various tissues (Schulte et al., 2011).
The VE–protein tyrosine phosphatase (PTP) was shown 
to associate with VE-cadherin and thereby enhance the adhesive 
function of VE-cadherin (Nawroth et al., 2002; Nottebaum 
et al., 2008). Permeability-inducing mediators such as VE 
growth factor (VEGF) and the attachment of leukocytes to 
endothelial cells (ECs) both stimulate a signaling pathway 
that triggers the dissociation of VE-PTP from VE-cadherin 
(Nottebaum et al., 2008; Vockel and Vestweber, 2013). This 
dissociation is necessary for the induction of vascular permea-
bility and for leukocyte extravasation in vivo. Evidence for this 
has been based on the analysis of knock-in mice where mod-
ified forms of VE-cadherin and VE-PTP, each containing a 
different binding site for a small molecular weight compound, 
had been knocked into the VE-cadherin locus (Broermann 
et al., 2011). In these mice, administration of the appropri-
ate compound inhibited the dissociation of VE-PTP from 
VE-cadherin and thereby attenuated the induction of vascu-
lar permeability and leukocyte extravasation, demonstrating 
the importance of VE-cadherin–associated VE-PTP for the 
control of endothelial junction stability in vivo. Moreover, 
HIF2α was recently reported to enhance endothelial barrier 
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integrity, in part through induced VE-PTP expression (Gong 
et al., 2015). In line with these findings, tyrosine phosphory-
lation of VE-cadherin has been demonstrated to be involved 
in the regulation of EC contacts in vitro (Allingham et al., 
2007; Turowski et al., 2008; Monaghan-Benson and Burridge, 
2009) and in vivo (Orsenigo et al., 2012; Wessel et al., 2014).
VE-PTP also associates with Tie-2 (Fachinger et al., 
1999), an endothelial tyrosine kinase receptor that regulates 
angiogenesis and can support the integrity of endothelial 
junctions. VE-PTP gene ablation causes embryonic lethality 
at embryonic day (E) 9.5 (Bäumer et al., 2006; Dominguez et 
al., 2007). This is caused by a defect in blood vessel remodel-
ing leading to enlarged and fused vessel structures. Antibodies 
against VE-PTP caused similar defects when incubated with 
explant cultures of allantois from WT mice, but not if the tis-
sue originated from Tie-2 gene–deficient mice (Winderlich 
et al., 2009). In addition, these antibodies against the extracel-
lular part of VE-PTP dissociated the phosphatase from Tie-2 
and caused phosphorylation of this receptor and signaling 
(Winderlich et al., 2009).
We have recently shown that a specific pharmacological 
inhibitor of VE-PTP catalytic activity, AKB-9778, activated 
Tie-2 in the mouse, and this correlated with suppression of 
ocular neovascularization and blocking of VEGF-induced vas-
cular leak (Shen et al., 2014). Although direct evidence for the 
relevance of Tie-2 is still missing, these results are in line with 
studies reporting that the Tie-2 ligand Angiopoietin-1 (Ang1) 
protects the vasculature against plasma leakage (Gamble et al., 
2000; Thurston et al., 2000; Mammoto et al., 2007; Gavard et 
al., 2008). In a mouse breast cancer model, AKB-9778 nor-
malized tumor vessels and delayed tumor growth (Goel et 
al., 2013). VE-PTP was also found to associate with VEGF 
receptor-2 (VEG FR-2; Mellberg et al., 2009), and this inter-
action was suggested to affect VEG FR-2 activity in endothe-
lial sprouts of mouse embryoid bodies (Hayashi et al., 2013).
Here we have analyzed how interference with VE-PTP 
activity influences endothelial junctions in adult mice and 
how this relates to the functions of Tie-2 and VE-cadherin. 
We found that conditional gene ablation of VE-PTP, as well 
as interference with antibodies or administering the inhibitor 
AKB-9778 each stabilized challenged endothelial junctions, 
thereby preventing enhanced permeability and leukocyte 
extravasation induced by inflammatory mediators. These ef-
fects required the expression of Tie-2 because blocking its 
expression in vivo reversed the effect of the VE-PTP inhib-
itor on endothelial junction integrity. Thus, VE-PTP inhibi-
tion stabilizes challenged endothelial junctions via Tie-2 and 
destabilizes them in the absence of Tie-2. Remarkably, the 
junction-stabilizing effect was even observed in mice con-
ditionally gene deficient for VE-cadherin. Inhibition of leak 
formation was accompanied by activation of Rap1 and cyto-
skeletal remodeling and reduced radial stress fiber formation. 
Our results reveal that inhibition of VE-PTP in vivo has op-
posing effects on endothelial junctions as the result of its differ-
ent effects on VE-cadherin and on Tie-2. Activation of Tie-2 
via inhibition of VE-PTP protects endothelial junctions 
against inflammation-induced destabilization and overrides 
the negative effect of VE-PTP inhibition on the adhesive 
function of VE-cadherin.
RES ULTS
Interference with VE-PTP by independent approaches 
stabilizes the endothelial barrier
We have recently shown that a pharmacological phosphatase 
inhibitor with high specificity for VE-PTP, AKB-9778, coun-
teracts VEGF-induced permeability across HUV EC monolay-
ers and VEGF- and histamine-induced vascular permeability 
in the skin of mice in a classical Miles assay (Shen et al., 2014). 
To verify whether these effects were indeed caused by the 
inhibition of VE-PTP and no other phosphatases, here we 
tested whether affinity-purified pAbs against the extracellular 
part of VE-PTP would have similar effects. HUV EC mono-
layers grown on transwell filters were preincubated either 
with control antibodies from preimmune serum or with af-
finity-purified antibodies against VE-PTP, followed by the in-
cubation with or without the permeability-inducing reagent. 
As shown in Fig. 1 (A and B), the substantial increase of per-
meability for 250-kD FITC-dextran, induced by thrombin or 
VEGF, was efficiently reduced with anti–VE-PTP antibodies. 
Similar results were obtained when we replaced the antibody 
treatment by incubation with 10 µM AKB-9778 for 30 min, 
whereas vehicle alone had no effect (Fig. 1 C). Both of these 
independent methods of VE-PTP inhibition induced tyrosine 
phosphorylation of the VE-PTP substrate Tie-2 (Fig. 1 D).
To test whether antibodies against the extracellular 
domain of VE-PTP would also stabilize the endothelial bar-
rier in vivo, we performed a Miles assay in C57BL/6 mice. 
Upon i.v. administration of 200 µg of affinity-purified anti–
VE-PTP antibodies or control antibodies, Evans blue was i.v. 
injected 30 min after antibody administration, and the skin 
was challenged 10 min later by intradermal injection of ei-
ther PBS or VEGF (25 ng in 50 µl). Anti–VE-PTP antibodies 
blocked VEGF-induced vascular permeability by 55% (±7%; 
Fig. 1 E). In the same mice, the anti–VE-PTP antibody treat-
ment stimulated tyrosine phosphorylation of Tie-2, as seen 
in immunoblots of Tie-2 that was immunoprecipitated from 
lung lysates (Fig. 1 F). Collectively, these results show that in-
hibiting VE-PTP with antibodies or with a small molecule in-
hibitor counteracts destabilization of EC contacts in vitro and 
in vivo, an effect that correlates with the activation of Tie-2.
VE-PTP gene ablation counteracts inflammation-
induced vascular permeability
To analyze the relevance of VE-PTP for the integrity of en-
dothelial junctions in vivo independent of pharmacologic 
inhibitors, we analyzed mice with an inactivated Ptprb gene. 
Because this gene is essential for embryonic development 
(Bäumer et al., 2006; Dominguez et al., 2007), we generated 
mice with exon 20 of the Ptprb gene flanked by loxP sites 
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to cause a truncation of the VE-PTP protein within the 17th 
fibronectin type III–like repeat of the extracellular domain 
because deletion of exon 20 creates an in-frame stop codon at 
the start of exon 21. As a consequence, this would remove the 
transmembrane and the catalytic domain of the phosphatase. 
Southern blot analysis of DNA of the generated mice with 
an external probe (not depicted) as well as PCR genotyping 
revealed the expected results (Fig. 2 B). To confirm that Cre 
excision of exon 20 results in a functional Ptprb-null allele, 
mice were bred to a Pgk-Cre driver line that expressed Cre 
recombinase at the one-cell embryo stage. Homozygous de-
letion resulted in embryonic lethality at E9.5 (not depicted), 
similar as shown before for gene-deficient mice where either 
exon 18 (Bäumer et al., 2006) or exon 1 (Dominguez et al., 
2007) had been constitutively deleted.
To inactivate Ptprb in postnatal ECs, Ptprblox/lox mice 
were bred to tamoxifen-inducible Pdgfb-iCre transgenics. To 
test the effect of Cre-induced deletion on VE-PTP protein 
expression, we performed immunoblots of primary ECs iso-
lated from the lungs of Pdgfb-iCre+, Ptprblox/lox (PtprbiECKO) 
mutants that had been repeatedly treated by i.p. injections of 
tamoxifen. pAbs against the first eight FN type III–like re-
peats of the extracellular part of VE-PTP recognized VE-PTP 
in immunoblots of cell lysates of ECs from WT mice but did 
not detect a truncated form of VE-PTP in lysates of ECs of 
the mutant mice (Fig. 2 C). Likewise, no truncated form of 
VE-PTP was detected in culture supernatants of these cells 
(Fig. 2 D). Thus, if the expectable truncated form of VE-PTP 
was expressed, it was most likely unstable. In agreement with 
this, VE-PTP was not detectable by FACS on primary ECs of 
these mice (not depicted).
To determine whether VE-PTP gene ablation would in-
fluence the integrity of endothelial junctions, we performed a 
Miles assay with WT mice and PtprbiECKO mutants. Based on 
i.v. injected Evans blue and intradermal challenge with VEGF 
or histamine, we found that permeability induction was clearly 
reduced in tamoxifen-treated PtprbiECKO mice (Fig. 2 E). Im-
munoblots of lung lysates of these mice probed with antibodies 
against the extracellular part of VE-PTP revealed that Cre-in-
duced gene ablation resulted in the loss of most of the VE-PTP 
Figure 1. Inhibiting VE-PTP reinforces 
endothelial barrier stability in vitro and 
in vivo. (A–C) Paracellular permeability for 
250-kD FITC-dextran was determined for HUV 
EC monolayers grown on transwell filters. 
Permeability was induced either with throm-
bin (A and C) or with VEGF (B; as indicated). 
Permeability of PBS-treated cells was set to 
100%. For VE-PTP targeting, cells were either 
treated with anti–VE-PTP pAbs (A and B) or 
with the VE-PTP inhibitor AKB-9778 (C; as in-
dicated). As a control, cells were treated with 
preimmune antibodies (control Ab) or solvent 
alone (vehicle). (D) Tie-2 was immunoprecipi-
tated from either untreated (−) or anti–VE-PTP 
antibody (αVE-PTP Ab)– or AKB-9778–treated 
HUV ECs (as indicated) and immunoblotted for 
anti–phospho-tyrosine (4G10) or anti–Tie-2 
(Tie-2). (E) Mice were injected i.v. with control 
IgG or anti-VEP TP antibodies (as indicated). 30 
min before the start of the Miles assay, Evans 
blue was i.v. injected, followed by intradermal 
injection of VEGF or PBS (as indicated) 10 min 
later. After 30 min, mice were sacrificed, and 
the dye was extracted from skin samples and 
quantified. (F) Tie-2 was immunoprecipitated 
from lung lysates of either control IgG (−)– 
or anti–VE-PTP antibody–injected mice and 
immunoblotted as in D. Data are pooled from 
three independent experiments with three 
replicates in each experiment (A–C) or two in-
dependent experiments with four to five mice 
per group in each experiment (E). Statistical 
significance was analyzed using the one-way 
ANO VA test, and for D the Mann-Whitney rank 
sum test was used. *, P ≤ 0.05; **, P ≤ 0.01; ***, 
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protein (Fig.  2  F). Strong inhibition of VEGF- and hista-
mine-induced vascular permeability was also seen with the VE-
PTP inhibitor AKB-9778 (24 mg/kg) in WT mice (Fig. 2 E), 
whereas it had no additional inhibitory effect on the induc-
tion of vascular permeability in PtprbiECKO mice, confirming 
the high specificity of the inhibitor for VE-PTP (Fig. 2 E). In 
agreement with these results, VE-PTP deletion and the VE-
PTP inhibitor both enhanced Tie-2 phosphorylation in vivo, 
as determined in phospho-tyrosine blots of Tie-2, immuno-
precipitated from lung lysates (Fig. 2 G). Again, the inhibitor 
had no additive effect on Tie-2 phosphorylation in PtprbiECKO 
mice (Fig. 2 G). These results demonstrate that the phosphatase 
inhibitor AKB-9778 stabilizes challenged EC contacts and ac-
tivates Tie-2 in vivo selectively via VE-PTP. Collectively, these 
results indicate that pharmacologic inhibition or genetic ab-
lation of VE-PTP counteracts destabilization of EC contacts.
VE-PTP inhibition stabilizes endothelial junctions via Tie-2
Because pharmacologic inhibition and genetic ablation of 
VE-PTP both stabilize endothelial barrier integrity and in-
Figure 2. Conditional Ptprb gene inacti-
vation in mice and analysis of its effect 
on vascular permeability. (A) A map of the 
relevant genomic region is shown, containing 
exon 20, flanked by loxP sites. Gene inactiva-
tion creates a stop codon at the start of exon 
21 that codes for the transmembrane domain 
of VE-PTP. (B) PCR genotyping using primers 
P1 and P2 resulted in 1,440-bp or 1,290-bp 
products for the mutant or WT allele, respec-
tively. (C and D) Immunoblots of VE-PTP of 
cell lysates (C) and of VE-PTP immunoprecip-
itates of culture supernatants (D) of primary 
ECs isolated from lungs of either Ptprblox/lox or 
of PtprbiECKO mice (as indicated), each treated 
repeatedly with i.p. injected tamoxifen. Blots 
were incubated with pAbs against the ex-
tracellular domain of VE-PTP or antibodies 
against VE-cadherin (as indicated; Ig-HC, IgG 
heavy chain). (E) Ptprblox/lox or PtprbiECKO mice 
were i.p. injected with tamoxifen daily for 5 
d. 5 d later, mice were either subcutaneously 
injected with AKB-9778 or with vehicle (as in-
dicated), and 30 min later, Evans blue was i.v. 
injected, followed by intradermal injection of 
PBS, VEGF, or histamine (as indicated) 10 min 
later. After 30 min, mice were sacrificed, and 
the dye was extracted from skin samples and 
quantified. (F and G) Total lung lysates (F) or 
Tie-2 immunoprecipitates (G) of mice from E 
were immunoblotted for VE-PTP or VE-cad-
herin (F) or for phospho-tyrosine (4G10) or 
Tie-2 (G) as indicated. Data are representative 
of at least two independent experiments (C, 
D, F, and G) and pooled from two indepen-
dent experiments with four mice per group 
in each experiment (E). Statistical significance 
was analyzed using the one-way ANO VA test. 
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Results 
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crease the phosphorylation of Tie-2, we asked whether Tie-2 
is required for the junction-stabilizing effect of the inhibitor. 
Therefore, we transfected HUV ECs with Tie-2 siRNA or 
control siRNA and tested the effect of 10 µM AKB-9778 or 
vehicle alone on thrombin-induced permeability of mono-
layers of these cells for FITC-dextran. As shown in Fig. 3 A, 
AKB-9778 blocked thrombin-induced permeability under 
control siRNA conditions, whereas this effect was no longer 
observed if Tie-2 expression was inhibited by siRNA. The 
expression of Tie-2 was inhibited by the siRNA treatment 
by 86%, and no effect was seen for VE-PTP or VE-cadherin 
(Fig. 3 C). Thus, the stabilizing effect of AKB-9778 on endo-
thelial junctions depends on Tie-2.
When similar experiments were performed without 
thrombin treatment, we found that baseline permeability 
of HUV EC monolayers was not affected by AKB-9778 if 
Tie-2 was still expressed (control siRNA), whereas the inhib-
itor enhanced permeability if Tie-2 expression was reduced 
(Fig.  3 B). The fact that AKB-9778 did not affect baseline 
permeability when Tie-2 was still expressed prompted us to 
test the effect of AKB-9778 and cartilage oligomeric matrix 
protein (Comp)–Ang1 on baseline permeability of confluent 
HUV ECs at different densities. We found clear inhibitory ef-
fects with AKB-9778 on confluent monolayers of cells seeded 
at 2.7-fold lower cell density, whereas the effect was lost at 
higher cell density (4.5 × 104 cells/cm2 vs. 1.2 × 105 cells/
cm2 grown for 54 h; Fig. 3 D). Because VE-PTP junctional 
expression and association with VE-cadherin are weak at low 
cell density and increase with higher confluence (Notte-
baum et al., 2008), we assume that only at high confluence 
the AKB-9778 effect on VE-cadherin compensates the effect 
on Tie-2, whereas at lower confluence the effect via Tie-2 
is dominant. In agreement with this, Comp-Ang1 inhibited 
permeability at both levels of confluence (Fig. 3 D).
In line with previously published Tie-2 silencing ex-
periments (Hakanpaa et al., 2015), inhibition of Tie-2 ex-
pression alone resulted in increased endothelial permeability 
(Fig. 3 B), suggesting that Tie-2 is necessary for cell contact 
integrity. Mechanistically, Tie-2 may support junction integ-
rity by counteracting Ang-2–integrin signaling, which desta-
bilizes cell contacts (Hakanpaa et al., 2015). In addition, the 
intrinsic kinase activity of Tie-2 may be responsible for rein-
forcing cell contact integrity.
The junction-destabilizing effect of AKB-9778 in the 
absence of Tie-2 is in line with the supportive effect of VE-
PTP for VE-cadherin (Nottebaum et al., 2008; Broermann 
et al., 2011). Potential VE-PTP substrates that are responsi-
ble for this effect are VE-cadherin–Y685 and plakoglobin 
(Nottebaum et al., 2008; Wessel et al., 2014), and both are 
phosphorylated after AKB-9778 treatment of ECs (not de-
picted). Other candidates would be VEG FR-2 (Hayashi et al., 
2013) or Src, which are both relevant for the phosphoryla-
tion of VE-cadherin. To test this, we either transfected HUV 
ECs with control siRNA or with Tie-2 siRNA and treated 
the cells with either vehicle alone or 5 µM AKB-9778 for 
30 min, followed by immunoprecipitation of VEG FR-2 or 
Src and immunoblotting either for phospho-tyrosine or for 
Src-pY418. As shown in Fig.  3 (E and G), AKB-9778 in-
duced VEG FR-2 tyrosine phosphorylation independent of 
the expression of Tie-2 but had no significant effect on Src 
phosphorylation. VEGF induced the phosphorylation of VEG 
FR-2 slightly more efficiently than AKB-9778 (Fig. 3 F).
To test whether Tie-2 is also responsible for the junc-
tion-stabilizing effect of AKB-9778 in vivo, we inhibited the 
expression of Tie-2 in mice by in vivo siRNA using a poly-
ethyleneimine-based transfection reagent (in vivo-jetPEI). 
As shown in Fig.  3  J, i.v. injection of Tie-2 siRNA could 
efficiently block the expression of Tie-2, as was analyzed by 
immunoblotting of lung lysates. Quantification of immuno-
blot signals for 13 control and 12 Tie-2 siRNA–treated mice 
revealed 74% (±4%) reduction of Tie-2 expression (Fig. 4 G). 
Mice treated with the transfection reagent in combination 
either with control siRNA or with a Tie-2 siRNA were 
analyzed for basal (Fig. 3 H) and for LPS-induced vascular 
permeability in the lung (Fig. 3 I). For LPS challenge, mice 
were exposed to aerosolized LPS for 40 min, and vascular 
permeability was determined by injecting Evans blue 4 h later 
for 15 min. As shown in Fig. 3 H, AKB-9778 had no effect 
on baseline vascular permeability when Tie-2 was expressed 
(ctrl siRNA condition). In contrast, Tie-2 siRNA treatment 
enhanced vascular permeability slightly (by 27 ± 10%), and 
administering AKB-9778 in addition enhanced permeability 
by an additional 43% (±13%; Fig. 3 H). LPS-induced perme-
ability in mice expressing normal levels of Tie-2 (ctrl siRNA) 
could be clearly counteracted with the AKB-9778 inhibitor, 
whereas LPS-induced permeability in Tie-2 siRNA–treated 
mice could no longer be inhibited with this compound 
(Fig. 3 I). Thus, in analogy to the in vitro results, Tie-2 ex-
pression was required for the protective effect of AKB-9778 
on inflammation-induced vascular permeability in the lung. 
Furthermore, under baseline conditions, inhibiting the ex-
pression of Tie-2 reverts the junction-stabilizing effect of the 
VE-PTP inhibitor into a junction-destabilizing effect (Fig. 3, 
B and H). Finally, Tie-2 expression is essential for baseline 
integrity of the blood vessel wall.
Inhibition of VE-PTP impedes transendothelial migration  
of leukocytes via activation of Tie-2
The stabilizing effect of the VE-PTP inhibitor AKB-9778 
on EC junctions prompted us to test whether this inhibi-
tor would also affect the transmigration of leukocytes. HUV 
EC monolayers were cultured on transwell filters, pretreated 
48 h before the test with either control siRNA or with Tie-2 
siRNA, followed 33 h later by incubation with 5 nM TNF 
and either 5  µM AKB-9778 or vehicle alone. The phos-
phatase inhibitor reduced transmigration of neutrophils by 
40% (±3.9%) if the cells had been pretreated with control 
siRNA (Fig.  4 A). Analogous to the permeability assays in 
Fig. 3, inhibiting the expression of Tie-2 by siRNA increased 
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Figure 3. Silencing of Tie-2 by siRNA eliminates 
the permeability-reducing effect of AKB-9778 
in vitro and in vivo. (A and B) Paracellular per-
meability for 250-kD FITC-dextran was determined 
for HUV ECs transfected with control siRNA or with 
Tie-2–targeting siRNA (as indicated) and grown on 
transwell filters. (A) Cells were treated with vehicle, 
thrombin, or a combination of thrombin and AKB-
9778 (as indicated). (B) Cells were treated with ei-
ther vehicle or AKB-9778, and basal permeability 
was analyzed (as indicated). (C) Total cell lysates of 
HUV ECs transfected with control siRNA or Tie-2–tar-
geting siRNA were immunoblotted for Tie-2, VE-PTP, 
VE-cadherin, and α-tubulin (as indicated). (D) HUV 
ECs were grown on transwell filters at low (4.5 × 104 
cell/cm2) and high (1.2 × 105 cells/cm2) confluence 
and treated for 30 min with 600 ng/ml Comp-Ang1, 
10  µM AKB-9778, or vehicle (as indicated) before 
permeability for 250-kD FITC-dextran was deter-
mined under baseline conditions. Permeability of ve-
hicle-treated cells was set to 100%. (E) VEG FR-2 was 
immunoprecipitated from HUV ECs transfected with 
either control or Tie-2–targeting siRNA that were ei-
ther treated with vehicle (−) or with AKB-9778 (+) 
for 30 min. Immunoprecipitates were immunoblot-
ted for phospho-tyrosine (4G10) and VEG FR-2. Total 
lysates were immunoblotted for Tie-2 and α-tubulin 
(as indicated). (F) VEG FR-2 was immunoprecipitated 
from HUV ECs that were either untreated (−) or treated 
with 5 µM AKB-9778 or 100 ng/ml VEGF for 30 min 
(as indicated). Immunoprecipitates were immuno-
blotted for phospho-tyrosine (4G10) and VEG FR-2 
(as indicated). Total lysates were immunoblotted for 
VEG FR-2 and Tie-2 (as indicated). (G) Src was immu-
noprecipitated from HUV ECs transfected with either 
control or Tie-2–targeting siRNA that were either 
treated with vehicle (−) or 5 µM AKB-9778 (+) for 30 
min. Immunoprecipitates were immunoblotted for 
Src-pY418 and total Src. Total lysates were immuno-
blotted for Tie-2 and VE-cadherin (as indicated). (H) 
Mice were i.v. injected with either control siRNA or 
Tie-2–targeting siRNA (as indicated) and 48 h later 
subcutaneously injected with either vehicle alone or 
AKB-9778, followed 45 min later by i.v. injection of 
Evans blue. After 15 min mice were sacrificed, the 
lung circulation was perfused, and the dye was ex-
tracted from the lung tissue and quantified. (I) Mice 
were treated with control or Tie-2 siRNA as in H and 
then subcutaneously injected with solvent (control 
or LPS group) or with AKB-9778, followed by expos-
ing them to nebulized LPS or saline (control) for 40 
min. 4 h later, mice were i.v. injected with Evans blue, 
and 15 min later, lung permeability was measured 
as in H. (J) Total lung lysates of mice from H were 
immunoblotted for the indicated antigens. Data are 
pooled from four independent experiments with at 
least three replicates in each experiment (A and B) or 
two independent experiments with at least three rep-
licates in each experiment (D) or five to six mice per group in each experiment (H–J) and representative of at least two independent experiments (C, E–G, 
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study showing that Tie-2 silencing enhanced transendothelial 
migration of cancer cells (Hakanpaa et al., 2015). This effect 
was further enhanced if the VE-PTP inhibitor was added 
to Tie-2 siRNA–pretreated cells (Fig.  4  A). Tie-2 expres-
sion was reduced by 90% (Fig. 4 B). Neither AKB-9778 nor 
Tie-2 siRNA treatment affected ICAM-1 expression levels 
(Fig. 4 C). AKB-9778 also inhibited transmigration of human 
T cells through HUV ECs toward stromal cell–derived factor 
Figure 4. Silencing of Tie-2 by siRNA 
eliminates the neutrophil transmigra-
tion-reducing effect of AKB-9778 in 
vitro and in vivo. (A) Human neutrophils 
were allowed to transmigrate toward the 
chemokine IL-8 through a monolayer of 
15-h TNF-stimulated HUV ECs on transwell 
filters, which were either treated with 5 µM 
AKB-9778 or vehicle alone and transfected 
either with control or with Tie-2 siRNA (as 
indicated). The number of neutrophils that 
migrated across control-transfected cells was 
set to 100%. (B) Total cell lysates of HUV ECs 
transfected with control siRNA or Tie-2–tar-
geting siRNA were immunoblotted for Tie-2 
and α-tubulin (as indicated). (C) HUV ECs were 
transfected with control siRNA or Tie-2 siRNA 
and treated with vehicle or TNF for 18 h and 
in addition with vehicle or 5  µM AKB-9778 
(as indicated). Total lysates were immuno-
blotted for ICAM-1, Tie-2, VE-cadherin, and 
α-Tubulin (as indicated). (D) Human T cells 
were allowed to transmigrate toward 100 ng/
ml SDF-1α through a monolayer of HUV ECs 
stimulated as in A with TNF and in addition 
with either vehicle or AKB-9778 on transwell 
filters. The number of T cells that migrated 
across vehicle-treated cells was set to 100%. 
(E) Mice were i.v. injected with either control 
siRNA or with Tie-2 siRNA (as indicated) and 
48 h later subcutaneously injected with either 
vehicle alone or AKB-9778 (as indicated), fol-
lowed 45 min later by exposing the mice to 
nebulized LPS for 40 min. 4 h later, mice were 
sacrificed, and neutrophils recruited to the 
alveolar space were isolated by a broncho-
alveolar lavage and counted. (F) Lungs were 
removed from mice 48  h after i.v. injection 
of control siRNA or Tie-2 siRNA, and lysates 
were immunoblotted for the indicated anti-
gens. (G) The mean in vivo Tie-2 knockdown 
efficiency of Tie-2–targeting siRNA in mu-
rine lungs was determined by quantification 
of Tie-2 and PEC AM-1 immunoblot signals 
in lung lysates of mice injected with either 
control or Tie-2 siRNA. For quantification, 13 
control siRNA– and 12 Tie-2 siRNA–injected 
mice were analyzed. Tie-2 signals were nor-
malized to PEC AM-1 signals and set to 100% 
for control siRNA–injected animals. Data are 
pooled from three independent experiments 
with three replicates in each experiment (A) 
or two independent experiments with six rep-
licates in each experiment (D) or five mice per group (E and F) and representative of at least two independent experiments (B, C, and F). Statistical 
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1α (SDF-1α; Fig. 4 D). Thus, inhibiting the activity of VE-
PTP inhibits neutrophil and lymphocyte diapedesis, and this 
effect requires the presence of Tie-2. However, upon suppres-
sion of the expression of Tie-2, the VE-PTP inhibitor effect is 
reversed. Again, this junction-destabilizing effect of AKB-9778 
at low levels of Tie-2 expression is in line with the supportive 
role of VE-PTP for the adhesive function of VE-cadherin.
Next, we tested the effect of the VE-PTP inhibitor on 
neutrophil recruitment into the lungs of LPS-challenged 
mice. AKB-9778 was injected at a single dose of 24 mg/kg 
subcutaneously into mice that had been treated 48 h before 
with ctrl siRNA. Mice inhaled aerosolized LPS for 40 min, 
and 4 h later neutrophils recruited into the lung were iso-
lated by a bronchoalveolar lavage. We found that AKB-9778 
inhibited neutrophil extravasation by 60% (Fig.  4  E). This 
inhibitory effect of AKB-9778 was strongly reduced when 
Tie-2 expression was suppressed by Tie-2 siRNA treatment 
(Fig.  4  E). Tie-2 expression was reduced by 70–80% by 
siRNA, as analyzed by immunoblots of lung lysates (Fig. 4, 
F and G). Thus, inhibition of VE-PTP attenuates leukocyte 
diapedesis in vitro and in vivo via Tie-2.
AKB-9778-mediated Tie-2 activation stabilizes 
endothelial junctions via Rap1
The opposing effects of VE-PTP inhibition on VE-cadherin 
function on the one hand and on junction stabilization via 
Tie-2 on the other hand raised the question by which mech-
anism AKB-9778 enhances junction stability. It has been 
suggested that Tie-2 activation stabilizes junctions via stimu-
lating Rac1, which causes deactivation of RhoA (Mammoto 
et al., 2007). In line with this, we found that both 10  µM 
AKB-9778 and 200 ng/ml Comp-Ang1 activate the GTPase 
Rac1 in HUV ECs (Fig. 5 A).
Next we tested whether AKB-9778 would reverse 
the activating effect of thrombin on the phosphorylation of 
nonmuscle myosin light chain (MLC). As shown in Fig. 5 B, 
incubation of HUV ECs for 2 min with 1 U/ml thrombin 
enhanced phosphorylation of MLC at Thr18 and Ser19, as 
was detected in immunoblots. This effect was clearly reduced 
by AKB-9778 (Fig. 5 B).
In agreement with these effects, we found that throm-
bin-enhanced formation of radial stress fibers in monolay-
ers of HUV ECs was reduced by AKB-9778, as was shown 
by F-actin staining (Fig. 5 C). Linearization of junctions by 
AKB-9778, as visualized by staining for VE-cadherin, pointed 
toward reduced mechanical tension on cell contacts (Fig. 5 C).
To identify signaling steps that would be triggered 
by VE-PTP inhibition upstream of the activation of Rac1, 
we tested for the activation of Rap1, a GTPase that is well 
known to stabilize EC junctions. We found that incubation 
of HUV ECs for 10 min with 10 µM AKB-9778 strongly 
enhanced the activation of Rap1 (Fig.  5  D). Knock-
ing down Rap1A and Rap1B simultaneously blocked 
the stimulatory effect of AKB-9778 on Rac1 activation 
(Fig. 5 E). In addition, siRNA for Rap1A and Rap1B also 
blocked the stabilizing effect of AKB-9778 on the barrier 
function of HUV EC monolayers challenged by thrombin 
and determined in permeability assays (Fig.  5  F). Rap1 
expression was reduced by 88% by siRNA, as analyzed by 
immunoblots of HUV EC lysates (Fig.  5 G). Thus, AKB-
9778 stimulates Rac1 and stabilizes EC contacts via Rap1.
Tie-2 activation by multimeric Ang1 was recently found 
to induce rapid redistribution of Tie-2 to the EC contacts 
(Fukuhara et al., 2008; Saharinen et al., 2008). It is an attractive 
hypothesis that this redistribution might be involved in the 
cell contact–stabilizing effect. To test this, we asked whether 
AKB-9778 would also induce the redistribution of Tie-2 to 
cell contacts. We found that 600 ng/ml Comp-Ang1 induced 
a strong accumulation of Tie-2 at cell contacts in fully conflu-
ent as well as in less confluent HUV EC monolayers; however, 
5 µM AKB-9778 had no such effect (Fig. 6, A and B). As con-
trols, we found that 5 µM AKB-9778 and 200 ng/ml and 1 
µg/ml Comp-Ang1 induced Tie-2 tyrosine phosphorylation 
(Fig.  6  C). In line with this, both AKB-9778 and Comp-
Ang1 efficiently reduced thrombin-induced permeability of 
HUV EC monolayers for 250-kD FITC-dextran (Fig. 6 D).
Collectively, we conclude that inhibition of VE-PTP 
stabilizes endothelial junctions via activation of Rap1, which 
acts upstream of Rac1 activation, and leads to reduced non-
muscle MLC phosphorylation and radial stress fiber forma-
tion. In addition, making use of this indirect way of Tie-2 
activation allowed us to show that stabilization of EC contacts 
by stimulating Tie-2 kinase activity does not require an in-
crease or accumulation of Tie-2 molecules at EC junctions. 
However, this does not rule out that it is Tie-2 at cell contacts, 
which mediates contact strengthening via Ang-1.
Analysis of endothelial junction integrity in conditional 
Cdh5lox/lox gene–deficient mice
To test the relevance of VE-cadherin for the VE-PTP/
Tie-2–induced stabilization of EC contacts, we generated 
conditional Cdh5 gene–deficient mice by flanking exon 2 
(containing the start codon) with loxP sites (Fig. 7, A and B). 
Homozygous Cdh5lox/lox mice expressing tamoxifen-induc-
ible Cdh5-iCre (Cdh5iECKO) or no Cre were stimulated at the 
age of 7 wk with tamoxifen daily for five consecutive days; 
2 d later, Evans blue was injected i.v. for 30 min, and extrav-
asated dye was determined in skin, heart, lung, and the brain. 
We found that inactivation of Cdh5 caused massive extrav-
asation of the dye in lung and heart, whereas no leaks were 
observed in skin and brain (Fig. 7 C). Ablation of Cdh5 led to 
an almost complete loss of VE-cadherin protein in brain, lung, 
heart, and skin, as was analyzed by immunoblotting tissue ly-
sates (Fig. 7, D and E). There was no difference in claudin-5 
expression detectable in brains of WT and Cdh5iECKO mice, 
as confirmed by immunoblotting of brain lysates (Fig. 7 D).
Despite the dramatic increase of vascular permeability 
in the lung of Cdh5iECKO mice, endothelial junctions in cap-
illaries, venules, and arterioles appeared intact when analyzed 
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between vessels in skin, heart, lung, and brain (Fig. 8 A). Like-
wise, the mean length of junctions was not affected by Cdh5 
gene inactivation (Fig.  8  C).Thus, the leakiness for plasma 
protein–adsorbed Evans blue was not accompanied by ul-
trastructural defects of junctions. Furthermore, histological 
analysis of sections of paraffin-embedded lungs did not reveal 
obvious vascular abnormalities or signs of bleeding (Fig. 8 B).
Because it was reported that loss of VE-cadherin leads 
to its replacement by N-cadherin in endothelial junctions 
(Giampietro et al., 2012), we tested whether this would be 
Figure 5. AKB-9778–triggered stimulation of 
Tie-2 stabilizes EC contacts via activation of 
Rap1. (A) HUV ECs were treated for 30 min with 
AKB-9778, COMP-Ang1, or vehicle (as indicated), 
followed by analyzing the activation level of Rac1 
by a luminescence-based G-LISA Rac1 activation 
assay. (B) HUV ECs were either pretreated with sol-
vent (vehicle) or with AKB-9778 for 30 min before 
solvent (−) or thrombin (+) was added and incu-
bated for 2 min (as indicated), followed by immu-
noblotting cell lysates for phospho-Thr18/Ser19 of 
nonmuscle MLC (pMLC2), MLC2, and VE-cadherin. 
(C) Confluent HUV EC monolayers were treated 
with either solvent (vehicle) or AKB-9778 for 30 
min before thrombin was added and incubated (as 
indicated) for 15 min, followed by staining of fixed 
and permeabilized cells for F-actin and VE-cad-
herin. Bars, 20 µm. (D) HUV ECs were either left 
untreated (−) or treated with AKB-9778 or with 
COMP-Ang1, followed by a pull-down assay for 
Rap1 and immunoblotting for this GTPase. (E) HUV 
ECs were transfected with control siRNA or Rap1 
siRNA. 72 h later, cells were treated with 10 µM 
AKB-9778 for 10 min, and Rac1 activity was mea-
sured by a pull-down experiment with the effector 
protein PAK, and active Rac1 was compared with 
total levels of Rac1. Total levels of Rap1 are shown 
at the bottom. (F) HUV ECs were silenced for Rap1 
as in E, grown on transwell filters, and treated for 
30 min with thrombin either in the presence of 
solvent (vehicle) or of AKB-9778 (as indicated). 
Permeability for 250-kD FITC-dextran was deter-
mined as for Fig. 1. (G) Total cell lysates of HUV ECs 
transfected with control siRNA or Rap1-targeting 
siRNA were immunoblotted for Rap1 and α-tu-
bulin (as indicated). Data are pooled from three 
independent experiments with three replicates 
in each experiment (A) or at least two indepen-
dent experiments (B–G). Statistical significance 
was analyzed using the one-way ANO VA test. 
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Results 
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the reason for the stability of endothelial junctions in the 
skin. Indeed, N-cadherin was up-regulated upon tamoxifen 
treatment of skin-derived primary ECs of Cdh5iECKO mice 
(Fig. 9 A), and N-cadherin replaced VE-cadherin at junctions 
(Fig. 9 B). However, in vivo inactivation of Cdh5, confirmed 
by whole mount stainings (Fig. 9 C) and immunoblots of the 
skin (Fig. 7 E), did not lead to the replacement of VE-cad-
herin by N-cadherin at endothelial junctions of blood vessels 
of the skin, as shown in whole mount stainings (Fig. 9 D). 
Nonjunctional, patchy staining of some vessels for N-cad-
herin was at the basal surface of ECs, colocalized with the 
perivascular cell marker NG2, and was seen independent of 
Cdh5 inactivation (Fig.  9  E). Remarkably, even β-catenin 
staining was not detected anymore at EC contacts of skin 
blood vessels upon inactivation of Cdh5 (Fig. 9 F). In com-
bination with our electron microscopy analysis, this surpris-
ing finding suggests that endothelial junctions, once they are 
formed in adult vessels, can maintain their structure even in 
the absence of cadherins.
VE-PTP inhibition stabilizes endothelial junctions  
in the absence of VE-cadherin
Because VE-cadherin is required for the stability of endothe-
lial junctions in the lung, we tested whether the Tie-2–me-
diated stabilizing effect of the VE-PTP inhibitor on vessel 
integrity in the lung would require VE-cadherin. Cdh5iECKO 
mice, and for controls Cdh5lox/lox mice without the Cre trans-
gene, were treated with tamoxifen as described in the previ-
ous section and exposed to aerosolized LPS for 40 min, and 
vascular permeability was determined by injecting Evans blue 
Figure 6. COMP-Ang1 and AKB-9778 
both stimulate tyrosine phosphorylation 
of Tie-2, but only Comp-Ang1 redistrib-
utes Tie-2 to EC contacts. HUV ECs were 
grown at low confluence (1.5 × 104 cells/cm2; 
A) and at high confluence (7 × 104 cells/cm2; 
B) and treated with solvent (vehicle), 5  µM 
AKB-9778, or 600 ng/ml COMP-Ang1 for 30 
min, followed by fixation, permeabilization, 
and staining for Tie-2 and VE-cadherin. Bars, 
20 µm. (C) Immunoprecipitates of Tie-2 from 
cell lysates of HUV ECs treated with reagents 
as indicated were immunoblotted for phos-
pho-tyrosine (4G10) and Tie-2. (D) HUV ECs 
were treated with solvent (vehicle), AKB-9778, 
or COMP-Ang1 for 30 min before thrombin 
was added (as indicated), and permeability for 
250-kD FITC-dextran was determined. Data 
are representative of at least two independent 
experiments (A and B) and pooled from two 
independent experiments with three replicates 
in each experiment (C). Statistical significance 
was analyzed using the one-way ANO VA test, 
and for D the Mann-Whitney rank sum test 
was used. **, P ≤ 0.01; ***, P ≤ 0.001. Results 
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4 h later for 5 min. As shown in Fig. 10 A, inactivation of 
Cdh5 increased lung vascular permeability, and exposure to 
LPS augmented the extravasation of Evans blue even further. 
Administration of AKB-9778 compensated the LPS-induced 
increase of vascular permeability in Cdh5iECKO mice. Gene 
inactivation resulted in a reduction of VE-cadherin to hardly 
detectable amounts, as determined by immunoblotting lung 
lysates for VE-cadherin (Fig. 10 C). Thus, blocking of inflam-
mation-induced vascular permeability by the VE-PTP inhib-
itor AKB-9778 does not require VE-cadherin. Interestingly, 
the lack of VE-cadherin could not be compensated by AKB-
9778. In agreement with this, we could also not block the 
permeability-increasing effect of i.v. injected anti–VE-cad-
herin mAb BV13 by AKB-9778 (Fig. 10 B).
Next we tested whether inflammation-induced leuko-
cyte extravasation would be enhanced by Cdh5 gene ablation 
and whether activation of Tie-2 by inhibition of VE-PTP 
could counteract this effect. Cdh5iECKO mice, and for control 
Cdh5lox/lox mice, were treated with tamoxifen as described in 
the previous section and exposed to aerosolized LPS for 40 
min, and 4 h later, neutrophils recruited into the lungs were 
removed by bronchoalveolar lavage and counted. We found 
that inactivation of Cdh5 did indeed enhance neutrophil ex-
travasation (Fig. 10 D). AKB-9778 attenuated LPS-induced 
neutrophil extravasation in mice no matter whether they 
expressed VE-cadherin or not. Again, AKB-9778–triggered 
Tie-2–mediated stabilization of endothelial junctions does 
not require VE-cadherin, and this inhibits neutrophil recruit-
ment into the inflamed lung.
We showed that the junction-stabilizing effect of AKB-
9778 is based on Tie-2–driven activation of Rap-1, which 
in turn activates Rap-1 (Fig. 5). To test whether these effects 
are indeed independent of VE-cadherin, we isolated lung ECs 
from Cdh5iECKO mice and treated them in culture for 54 h 
either with 4-hydroxytamoxifen or solvent alone, followed by 
a pull-down assay for Rap-1 or Rac-1. As shown in Fig. 10 
(E and F), activation of both GTPases by AKB-9778 was seen 
independent of the presence of VE-cadherin. Efficiency of 
Cdh5 inactivation was demonstrated by immunoblotting cell 
lysates for VE-cadherin.
Figure 7. Conditional Cdh5 gene inacti-
vation in mice and analysis of its effect 
on vascular permeability. (A) A map of 
the relevant genomic region is shown, with 
ATG-containing exon 2, flanked by loxP sites. 
P1 and P2 represent oligonucleotides used 
for PCR screening. (B) PCR genotyping using 
primers P1 and P2 resulted in 565-bp or 520-
bp products for the mutant or WT allele, re-
spectively. (C) Cdh5lox/lox or Cdh5iECKO mice were 
i.p. injected with tamoxifen daily for 5 d. 2 d 
later, Evans blue was i.v. injected, mice were 
sacrificed after 30 min, the body circulation 
was perfused, and the dye was extracted from 
samples of various organs (as indicated) and 
quantified. (D and E) Lysates of tissue samples 
from brain (D) and lung, heart, and skin (E) 
of tamoxifen-treated Cdh5lox/lox and Cdh5iECKO 
mice were immunoblotted for the indicated 
antigens. Data are pooled from at least two 
independent experiments with five to six mice 
per group in each experiment (C and D). Statis-
tical significance was analyzed using the one-
way ANO VA test. **, P ≤ 0.01; ***, P ≤ 0.001. 
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DIS CUSSI ON
In this study, we report on the dual role of VE-PTP for the 
regulation of endothelial junctions and the consequences for 
vascular permeability and leukocyte extravasation in vivo. 
Disruption of VE-PTP activity by genetic ablation or phar-
macologic inhibition with extracellular domain antibodies 
or the selective phosphatase inhibitor AKB-9778 protected 
against the induction of vascular permeability by various in-
flammatory mediators. In addition, inhibition of VE-PTP also 
blocked neutrophil recruitment into the lungs of LPS-chal-
lenged mice. Targeting the expression of Tie-2 enabled us to 
demonstrate the following: first, that Tie-2 is responsible for 
the protective effect of VE-PTP inhibition on vessel integrity; 
second, that Tie-2 expression is required to maintain base-
line integrity of the vessel wall; and third, that the absence of 
Tie-2 enables VE-PTP inhibition to destabilize endothelial 
junctions, which highlights the supportive effect of VE-PTP 
for the adhesive function of VE-cadherin in vivo. Surprisingly, 
our results demonstrate that the stabilizing effect of AKB-
9778 on junctions via Tie-2 overrides the destabilizing effect 
caused by inhibiting VE-cadherin–mediated adhesion. More-
over, and in line with this, AKB-9778 could even stabilize 
endothelial junctions and vessel integrity in the absence of 
VE-cadherin. This junction-stabilizing effect of AKB-9778 is 
based on Tie-2–driven activation of Rap1, which in turn ac-
tivates Rac1 and leads to the dissolution of radial stress fibers.
Figure 8. Endothelial Junctions of Cdh5i-
ECKO mice appear largely normal in lung, 
heart, skin, and brain, and lungs show no 
obvious vascular malformation or hemor-
rhage. (A) Electron microscopy of endothe-
lial junctions in skin, heart, lung, and brain 
of tamoxifen-treated Cdh5iECKO mice. Note 
that junctions (asterisks) appeared largely 
normal. BM, basement membrane; PVC, peri-
vascular cells. (B) Paraffin sections of the 
lung of tamoxifen-treated Cdh5lox/lox mice and 
Cdh5iECKO mice were stained for the endothe-
lial marker endomucin. Insets show repre-
sentative sections at a three-times-higher 
magnification. No signs of bleeding or tissue 
damage were observed. Bars: (A) 1 µm; (B) 
100 µm. (C) The mean length of endothelial 
junctions was determined in electron micros-
copy pictures of skin, heart, lung, and brain 
in tamoxifen-treated Cdh5lox/lox and Cdh5iECKO 
mice using the software Fiji. For the quanti-
fication, 86 junctions in the skin, 15 junctions 
in the heart, 51 junctions in the lung, and 41 
junctions in the brain were analyzed. Data are 
representative of at least two independent ex-
periments with at least three mice per group 
in each experiment (A) and two independent 
experiments with at least two mice in each 
experiment (B). Statistical significance was an-
alyzed using the one-way ANO VA test. Results 
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Figure 9. VE-cadherin is replaced by N-cadherin in cultured ECs of Cdh5iECKO but not by N-cadherin or other cadherins in blood vessels of the skin. 
(A) ECs were isolated from the skin of Cdh5iECKO mice and treated with solvent (EtOH) or 4-hydroxytamoxifen (Tam), and cell lysates were immunoblotted for 
the indicated antigens. (B) ECs isolated from the skin of Cdh5iECKO mice were treated with solvent (EtOH) or 4-hydroxytamoxifen and stained for the indicated 
antigens. (C and D) Whole mount stainings of the skin of Cdh5lox/lox and Cdh5iECKO mice for the indicated antigens. Insets in D show the indicated sector at a 
three-times-higher magnification. (E) Whole mount stainings of the skin of WT mice stained for N-cadherin and the pericyte marker NG2. Arrows mark white 
areas indicating NG2/N-cadherin colocalization. (F) Whole mount stainings of the skin of Cdh5lox/lox and Cdh5iECKO mice for the indicated antigens. Data are 
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Although AKB-9778 is a highly specific inhibitor of the 
catalytic activity of VE-PTP (Shen et al., 2014), the present 
study is the first to demonstrate that this inhibitor stabilizes ves-
sel integrity indeed via VE-PTP and that the substrate respon-
sible for this effect is Tie-2. The essential role of VE-PTP for 
the junction-stabilizing effect of AKB-9778 was demonstrated 
because this effect of the inhibitor was no longer observed 
in PtprbiECKO mice. The question of which VE-PTP substrate 
would be responsible for the junction-stabilizing effect is im-
portant in light of other substrates that have been described. 
Besides VE-cadherin and Tie-2, VE-PTP had been reported to 
interact with and to affect the activity of the VEG FR-2, an 
interaction that was suggested to be relevant for endothelial 
sprouting (Mellberg et al., 2009; Hayashi et al., 2013). Further-
more, other tyrosine kinase receptors were described as possible 
substrates based on binding to a phosphatase-trapping mutant 
(Sakuraba et al., 2013). In this context, it is important that ex-
pression of Tie-2 was indeed required for the AKB-9778–sta-
bilizing effect on endothelial junctions.
Several substrates of VE-PTP are likely to be involved 
in the junction-destabilizing effect of AKB-9778 under con-
ditions of low or no Tie-2 expression. These are VE-cadherin 
itself and plakoglobin (Nottebaum et al., 2008; Wessel et al., 
2014) and VEG FR-2 (Hayashi et al., 2013), which are in-
volved in the regulation of junctions. Whether other poten-
tial substrates of VE-PTP (Sakuraba et al., 2013) are relevant 
for the stabilizing effect of VE-PTP on endothelial junc-
tions is at present unknown.
Stimulation of Tie-2 by Ang-1 protects the vasculature 
against plasma leaks (Gamble et al., 2000; Thurston et al., 
2000). Various signaling mechanisms were suggested to me-
diate this effect. Ang-1 was shown to trigger the activation 
Figure 10. AKB-9778 counteracts 
LPS-induced leakiness and neutrophil re-
cruitment in the lung even in the absence 
of VE-cadherin. (A) Cdh5lox/lox or Cdh5iECKO 
mice were i.p. injected with tamoxifen daily 
for 5 d and, 2 d later, subcutaneously injected 
with solvent (ctrl or LPS group) or with AKB-
9778 and then exposed to nebulized LPS or 
saline (ctrl) for 40 min. 4 h later, mice were i.v. 
injected with Evans blue and 5 min later sac-
rificed; the lung circulation was perfused, and 
the dye was extracted from the lung tissue 
and quantified. (B) Mice were subcutaneously 
injected with either vehicle alone or AKB-
9778 and 30 min later i.v. injected with either 
60 µg/mouse control IgG or BV13 (as indi-
cated). 2 h later, Evans blue was i.v. injected. 
After 15 min, mice were sacrificed, the lung 
circulation was perfused, and the dye was ex-
tracted from the lung tissue and quantified. 
(C) Total lung lysates of mice from D were im-
munoblotted for the indicated antigens. (D) 
Cdh5lox/lox or Cdh5iECKO mice were treated with 
tamoxifen and LPS as in A, and extravasated 
neutrophils were isolated by bronchoalveo-
lar lavage and counted. (E and F) ECs were 
isolated from the lungs of Cdh5iECKO mice, 
treated in culture for 54 h with solvent (EtOH) 
or 4-hydroxytamoxifen (Tam), and stimulated 
for 30 min either with vehicle or AKB-9778 
(as indicated), followed by a pull-down assay 
for Rap1 (E) or Rac1 (F) and immunoblotting 
for the analyzed GTPase. Total cell lysates 
were immunoblotted for VE-cadherin and 
α-tubulin (as indicated). Data are pooled 
from two independent experiments with four 
mice per group in each experiment (A) or two 
to three mice per group in each experiment 
(B) or five mice per group in each experiment 
(D) and representative of at least two independent experiments (C, E, and F). Statistical significance was analyzed using the one-way ANO VA test. *, P ≤ 









Published December 7, 2015
2281JEM Vol. 212, No. 13
of RhoA, which caused the sequestration of Src by mDia, 
and thereby inhibition of VEGF-induced VE-cadherin phos-
phorylation and endocytosis (Gavard et al., 2008). In line with 
this, it was reported that Ang1 triggers the recruitment of 
the RhoA-specific GEF Syx to endothelial junctions, which 
supported RhoA-mediated activation of mDia (Ngok et al., 
2012). Others reported that stimulation of Tie-2 leads to the 
activation of Rac1, which triggered via p190RhoGAP the 
deactivation of RhoA, which in turn blocked rearrangements 
of the actin cytoskeleton caused by inflammatory mediators 
(Mammoto et al., 2007; David et al., 2011). Our results are 
in line with the latter studies. AKB-9778–mediated stimula-
tion of Tie-2 activated Rac1 and dissolved the formation of 
actomyosin-based radial stress fibers, releasing the tension on 
endothelial junctions. With the activation of Rap1, we have 
identified an essential step upstream of Rac1, via which Tie-2 
stabilizes endothelial junctions. In addition to Rac-1, Rap-1 
could also more directly modulate the activity of RhoA via 
the RhoGAP ArhGAP29 (Post et al., 2013).
Rap1 activation, although hitherto unknown as a sig-
naling target of Tie-2, is well established as a signaling step 
that leads to the reinforcement of endothelial junctions. This 
is achieved by two “parallel” pathways, the dissolution of 
radial stress fibers via suppression of the Rho–Rock–non-
muscle myosin II pathway, and by the formation of circum-
ferential actin bundles via activation of Cdc42 (Ando et al., 
2013). Both of these effects on radial stress fibers and cir-
cumferential actin filaments were observed with AKB-9778 
in HUV ECs (Fig.  5). It is reasonable to assume that these 
effects would enhance the adhesive activity of VE-cadherin, 
and it has indeed been demonstrated very convincingly that 
activation of Rap1 reinforces VE-cadherin–mediated endo-
thelial junction integrity (Fukuhara et al., 2005; Kooistra et 
al., 2005; Mochizuki, 2009). Remarkably, however, our results 
indicate that the Tie-2/Rap1-mediated effects on the acto-
myosin cytoskeleton are even able to reinforce endothelial 
junctions in the absence of VE-cadherin. Our results do not 
argue against mechanisms whereby Tie-2/Rap1 signaling en-
hances VE-cadherin–mediated adhesion, but they suggest that 
this signaling pathway is not essential to stabilize endothelial 
junctions via Tie-2 stimulation in vivo.
It has been demonstrated that Ang1 triggers the re-
distribution of Tie-2 together with VE-PTP to endothelial 
junctions in endothelial monolayers, whereas scattered mo-
bile ECs accumulate Tie-2 at cell matrix contacts (Fukuhara 
et al., 2008; Saharinen et al., 2008). These studies established 
that distinct Tie-2 signaling complexes were recruited to dif-
ferent sites in quiescent and mobile cells. This explained how 
Tie-2 manages to stimulate different signaling pathways in 
vascular quiescence and angiogenesis. Our results demon-
strate that the redistribution of Tie-2 to cell contacts is not 
automatically triggered by activation of Tie-2 kinase activity, 
but requires the binding of Ang-1.
The fact that stimulation of Tie-2 by the VE-PTP in-
hibitor AKB-9778 stabilizes challenged endothelial junctions 
even in the absence of VE-cadherin is noteworthy for at least 
two reasons. First, this explains why the negative effect of 
AKB-9778 on the adhesive function of VE-PTP–associated 
VE-cadherin does not jeopardize the ability of AKB-9778 
to reinforce junction integrity via Tie-2. Second, our results 
suggest that inflammation-induced opening of endothelial 
junctions is a two-step mechanism. It does require reduc-
tion of the adhesive function of VE-cadherin, as has been 
shown before with mutant knock-in mice expressing either 
a VE-cadherin–α-catenin fusion protein or VE-cadherin ty-
rosine mutants replacing endogenous VE-cadherin (Schulte 
et al., 2011; Wessel et al., 2014). In addition to the weakening 
of the adhesive integrity of endothelial junctions and inde-
pendent of this, inflammatory stimuli open endothelial junc-
tions via enhancing actomyosin-mediated pulling forces on 
cell contacts. AKB-9778–induced Tie-2 activation can abro-
gate this effect. It was unexpected that inflammation-induced 
effects on the actomyosin cytoskeleton further enhanced 
the opening of endothelial junctions even in the absence of 
VE-cadherin. Likewise, it is interesting that dampening the 
formation of radial stress fibers via Rap1 activation could 
still stabilize challenged endothelial junctions even when 
VE-cadherin was absent.
VE-cadherin is very well established as an adhesion 
molecule of dominant importance for the formation and 
the stability of endothelial junctions (Dejana and Vestweber, 
2013). Therefore, we were surprised to observe no leak for-
mation in skin and brain despite efficient Cdh5 gene inacti-
vation even at 7 d after the onset of Cre expression. In line 
with this, antibodies against VE-cadherin enhanced vascular 
permeability in lung and heart within hours but had no ef-
fect in skin and brain (Corada et al., 1999). However, lack 
of antibody-induced leak formation in skin and brain could 
have been caused by an insufficient accessibility of VE-cad-
herin for the antibodies. The present results circumvent this 
limitation. We can, however, not fully exclude that low-level 
leakage of plasma content might occur over longer time pe-
riods. In fact, at 17–20 d after onset of Cre expression, we 
detected edema formation in the dermis (unpublished data). 
This could either be caused by subtle junctional defects or by 
insufficient heart function.
Cdh5 gene–inactivated mice survived for at least 20 d. 
This demonstrates that tight junctions of the blood–brain 
barrier (BBB) were not dramatically affected and that main-
tenance of BBB integrity does not require VE-cadherin. For 
comparison, Cldn5−/− mice die within 10 h after birth as the 
result of a defective BBB (Nitta et al., 2003). In agreement 
with this, we detected normal levels of claudin-5 in brain 
lysates of Cdh5iECKO mice at day 7 after onset of Cre expres-
sion. Because absence of VE-cadherin was reported to cause 
a loss of claudin-5 expression in cultured ECs and in frag-
ments of endothelial clusters that formed in allantois explant 
cultures of Cdh5−/− mice (Taddei et al., 2008), we assume 
that VE-cadherin is relevant for the expression of claudin-5 
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fully established blood vessels do not need VE-cadherin to 
maintain claudin-5 expression and tight junction integrity.
We did not detect any obvious defects of endothelial 
junctions in Cdh5iECKO mice by ultrastructural analysis of 
vessel sections in skin and brain. Even lung and heart endo-
thelial junctions looked largely normal, despite the enhanced 
leakiness for plasma proteins. We can exclude that another 
cadherin was compensating the loss of VE-cadherin in skin 
blood vessels because we could neither detect N-cadherin 
nor β-catenin at endothelial junctions in skin whole mounts. 
In contrast, in vitro we found that N-cadherin was up-reg-
ulated in cultured primary ECs upon inactivation of Cdh5 
and was found at junctions, in line with a previous study (Gi-
ampietro et al., 2012). We conclude that in vivo the loss of 
VE-cadherin in fully established blood vessels in the adult 
skin is not compensated by other cadherins. Thus, it is re-
markable that endothelial adherens junctions in established 
blood vessels in skin and brain can be maintained in the ab-
sence of cadherins. Furthermore, enhanced basal permeability 
for plasma proteins in lung and heart caused by the absence of 
VE-cadherin is not accompanied with the complete destruc-
tion of junctions, but rather with a more subtle destabilization 
that does not correspond with damage that would be detect-
able by electron microscopy.
In conclusion, our results highlight the significance and 
interrelationship of VE-cadherin, Tie-2, and VE-PTP as reg-
ulators of endothelial junctions and vessel integrity in vivo. 
We show that inhibition of VE-PTP, although blocking its 
support for associated VE-cadherin, strengthens junction in-
tegrity via Tie-2. This latter effect relies on Rap1 that stim-
ulates the dissolution of radial stress fibers and can support 
junction strengthening even in the absence of VE-cadherin. 
Our results suggest that inflammation-induced weakening 
of endothelial junctions is a two-step process that requires 
targeting of VE-cadherin and/or associated proteins (Schulte 
et al., 2011; Wessel et al., 2014) plus interference with the 
actomyosin system. The latter of these effects is dampened 
by activation of Tie-2. Targeting of VE-cadherin is necessary 
but not always sufficient for opening of endothelial junctions 
in vivo because VE-cadherin gene inactivation had only dra-
matic effects on junction stability in organs exposed to strong 
mechanic challenge, such as lung and heart. Especially the 
stability of the BBB several weeks after VE-cadherin gene 
inactivation was surprising. This unexpected stability of en-
dothelial junctions in the absence of VE-cadherin may be ex-
plained by stability-enforcing structures such as the basement 
membrane and perivascular cells in established adult blood 
vessels. Furthermore, other adhesion molecules might be rel-
evant for the stability of endothelial junctions, in addition to 
VE-cadherin. Revealing their identity will be an interest-
ing goal for the future.
MAT ERIALS AND MET HODS
Cell culture and reagents. HUV ECs were cultured in EBM-2 
medium supplemented with SingleQuots (Lonza). Primary 
ECs from lung of WT or gene-inactivated mice were isolated 
and cultured as previously described (Schulte et al., 2011). For 
isolation of ECs from skin, tails were cut at the base and trans-
ferred into sterile HBSS/1% Pen/Strep before the skin was 
removed from the tails and cut into 20-mm-long fragments. 
The fragments were incubated in 5% Dispase/PBS for 60 min 
at 37°C with gentle agitation to separate epidermis from der-
mis. Dermal fragments were washed in HBSS/1% Pen/Strep, 
transferred into Collagenase A (Roche) solution, and pro-
cessed as for lung EC isolation.
Human T cells were isolated from human peripheral 
blood using the Dynabeads Untouched Human T Cells kit 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions and preactivated for 2–5 d in T cell medium 
(RPMI, 20% FCS, 2% glutamine, 1% penicillin/strepto-
mycin, 1% Na-pyruvate, 1% nonessential amino acids, and 
0.1% β-Mercaptoethanol) containing 10 ng/ml recombi-
nant human IL2 (PeproTech) and 2 µg/ml Phytohemagglu-
tinin-M (Roche). PMNs from human blood were isolated 
by density gradient centrifugation using Histopaque 1077 
and 1119 (Sigma-Aldrich). The phase containing the gran-
ulocytes was removed, and cells were washed twice in wash 
buffer (HBSS−/−, 25 mM Hepes, pH 7.3, and 10% FCS) be-
fore erythrocytes were lysed by incubation in 0.15 M NH4Cl, 
1 mM KHCO3, and 0.1 mM Na2EDTA for 4 min at room 
temperature. PMNs were used for transmigration assays 
directly after isolation.
The VE-PTP inhibitor AKB-9778 (Aerpio Therapeu-
tics) was used as a 10 mM (6.07 mg/ml) stock solution in 5% 
glucose/H2O. The following additional reagents were used: 
recombinant human TNF (PeproTech), IL-8 (R&D Systems), 
murine and human VEGF165 (PeproTech), human Thrombin 
(EMD Millipore), histamine (Sigma-Aldrich), COMP-Ang1 
(G.Y. Koh), gelatin (Sigma-Aldrich), fluorescent mounting 
medium (Dako), 250-kD FITC-dextran (Sigma-Aldrich) and 
Dispase (Roche), 4-hydroxytamoxifen (Sigma-Aldrich), and 
tamoxifen (Sigma-Aldrich).
Antibodies. The following antibodies were used: pAb VE42 
(Broermann et al., 2011) and pAb C5 against mouse VE-cad-
herin (Gotsch et al., 1997), pAb against human VE-cadherin 
(C-19; Santa Cruz Biotechnology, Inc.), murine pAb PTP 1–8 
against the extracellular fibronectin type III–like domains 1–8 
of VE-PTP (Winderlich et al., 2009), pAb VE-PTP-C against 
VE-PTP (Nawroth et al., 2002), mAb against PEC AM-1 
(1G5.1 and 5D2.6; Wegmann et al., 2006), pAb against PEC 
AM-1 (M-20; Santa Cruz Biotechnology, Inc.), mAb against 
N-cadherin (32/N-cadherin; BD), mAb against β-catenin 
(14/β-catenin; BD), mAb against plakoglobin (15/γ-catenin; 
BD), mAb against α-catenin (5/α-catenin; BD), mAb against 
p120-catenin (98/pp120; BD), pAb against β-catenin (Santa 
Cruz Biotechnology, Inc.), mAb against phosphotyrosine 
(4G10; Merck Millipore), mAb against α-tubulin (B-5-1-2; Sig-
ma-Aldrich), mAb 3G1 against Tie-2 (Koblizek et al., 1997), 
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against pMLC-2 (Cell Signaling Technology), pAb against 
Claudin-5 (Invitrogen), pAb against NG2 (Merck Millipore), 
mAb against Rac1 (102/Rac1; BD), pAb against Rap1 (Merck 
Millipore), mAb against murine Endomucin (V7C7.1; Mor-
gan et al., 1999), pAb against ICAM-1 (M-19; Santa Cruz 
Biotechnology, Inc.), mAb against human Tie-2 (D9D10; Cell 
Signaling Technology), pAb against Src-pY418 (Life Technol-
ogies), pAb against c-Src (SRC2; Santa Cruz Biotechnology, 
Inc.), mAb against VEG FR-2 (55B11; Cell Signaling Tech-
nology), and Phalloidin–Alexa Fluor 568 or –Alexa Fluor 647 
(Invitrogen). Secondary antibodies were purchased from Di-
anova. Alexa Fluor 488–, Alexa Fluor 568–, and Alexa Fluor 
647–coupled antibodies were purchased from Invitrogen.
Generation of conditional Cdh5 gene–inactivated mice. 
Cdh5lox/lox mice were generated by flanking the ATG-con-
taining exon 2 with loxP sites and inserting a neomycin se-
lection cassette (flanked by Frt sites) upstream of the 3′ loxP 
site by homologous recombination of mouse embryonic stem 
cells. The targeting vector contained a 6.9-kb-long arm 5′ of 
exon 2 and the loxP site–flanked exon 2, followed by an FRT-
flanked neo cassette and a 1.5-kb short arm. Neomycin-resis-
tant clones were screened by PCR and Southern blot analysis. 
Positive embryonic stem cell clones were injected into blas-
tocysts of C57BL/6 mice to generate chimeras, which were 
mated with C57BL/6 mice. The FRT-flanked neo cassette was 
excised by breeding with mice expressing Flp recombinase. To 
inactivate Cdh5 in postnatal ECs, Cdh5lox/lox mice were bred 
to tamoxifen-inducible Cdh5(PAC)-CreERT2 (Cdh5-iCre) 
transgenics (Wang et al., 2010), resulting in Cdh5iECKO mice. 
Mice were generated in cooperation with Genoway (Lyon) 
and backcrossed on the C57BL/6 mice background for at 
least nine generations. The following primers were used for 
genotyping: RMCE_for (5′-GAA GAGCT TTCGG GCTGG 
AATGA CC-3′) and RMCE_rev (5′-GGA TGATA TGGTA 
GCAGG TGTTG GGG-3′), generating a 520-bp PCR prod-
uct for WT and a 565-bp PCR product in Cdh5lox/lox mice. In 
addition, genotyping for the Cre gene was performed using 
the primers Cre_for (5′-GCC TGCAT TACCG GTCGA-3′) 
and Cre_rev (5′-GTG GCAGA TGGCG CGGCA-3′), gener-
ating either a 700-bp or no product.
Generation of conditional Ptprb gene–inactivated mice. 
Ptprblox/lox mice were generated by flanking exon 20 with 
loxP sites and inserting a neomycin resistance cassette (flanked 
by Frt sites) upstream of the 3′ loxP sites by homologous re-
combination in mouse embryonic stem cells. The targeting 
vector contained a 3.4-kb short arm 5′ of exon 20 and the 
loxP site–flanked exon 20 followed by the FRT site–flanked 
neo cassette and a 10.9-kb long arm. Generation of Ptprblox/
lox mice backcrossed on the C57BL/6 mice background was 
performed as described for the Cdh5lox/lox mice. To inactivate 
Ptprb in postnatal ECs, Ptprblox/lox mice were bred to tamox-
ifen-inducible Pdgfb-iCre transgenics (Claxton et al., 2008), 
resulting in PtprbiECKO mice. Mice were backcrossed on the 
C57BL/6 mice background for at least nine generations. To 
confirm that Cre excision of exon 20 results in a functional 
null Ptprb allele, mice were bred to a Pgk-Cre driver line 
(Lallemand et al., 1998) that expressed Cre recombinase al-
ready at the one-cell embryo stage. The following primers 
were used for genotyping: A/B geno S4 (5′-TGA ACCCT 
GAAGA GTCTC ACGTC CTTAC-3′) and A/B geno AS3 
(5′-GCC TGCAT GTATG CCCAC GAGAT-3′), generating a 
1,290-bp PCR product for WT and a 1,440-bp PCR prod-
uct in Cdh5lox/lox mice. All animal experiments were approved 
by the Landesamt für Natur, Umwelt und Verbraucherschutz 
Nordrhein-Westfalen. Animals were kept in a barrier facility 
under special pathogen–free conditions.
Tamoxifen treatment. For in vivo application, 100 mg tamox-
ifen was mixed with 100 µl ethanol and 5 ml peanut oil and 
dissolved for 30 min in a water bath at 37°C using ultrasound. 
100 µl of this solution was injected i.p. into PtprbiECKO and 
Cdh5iECKO mice daily for five consecutive days, and mice 
were used for assays 2 d later (Cdh5iECKO mice) or 5 d later 
(PtprbiECKO mice). Primary ECs of Cdh5iECKO mice were 
treated with 2 µM 4-hydroxytamoxifen, the active metabolite 
of tamoxifen, in culture medium for 2–3 d.
Immunofluorescence staining. For in vitro stainings, cells 
were seeded on fibronectin (HUV ECs)- or gelatin (primary 
mouse ECs)-coated chamber slides (Lab-Tek, 8 wells, glass) 
and grown to confluence before they were stimulated as de-
scribed previously (Schulte et al., 2011), washed with PBS, 
fixed with 4% PFA/PBS for 10 min at room temperature, and 
permeabilized using 0.5% Triton X-100/PBS for 5 min at 
room temperature, followed by blocking with 3% BSA for 
1 h and incubation with primary antibodies. Primary anti-
bodies were detected with Alexa Fluor 488–, Alexa Fluor 
568–, or Alexa Fluor 64–coupled secondary antibodies. Fluo-
rescence signals were detected using a confocal laser-scanning 
microscope (LSM 780 inverted microscope; Carl Zeiss). For 
skin whole mount stainings, ears of mice were cut off at the 
base, and initial fixation for 10 min with 4% PFA in PBS was 
performed before they were split into halves. Staining on ear 
halves was performed as previously described for Cremaster 
(Schulte et al., 2011).
Immunohistochemistry. For histological examination of lung 
paraffin sections, mice were anesthetized using ketamine/
xylazine. After lung perfusion with PBS, mice were intubated 
and lungs were inflated with 1 ml of 4% PFA/PBS. The tra-
chea was tied, and lung and heart were removed en bloc and 
fixed in 4% PFA/PBS over night at 4°C. Afterward, the heart 
was removed, and the lung was cut into lobes, dehydrated, 
embedded in paraffin, and sectioned at 5 µm using a micro-
tome. Sections were mounted on slides (Superfrost Plus; 
Menzel), dewaxed, rehydrated, and immunostained for en-
domucin using the antibody V7C7.1 as described previously 
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ABC kit (Vector Laboratories) to detect the primary antibod-
ies. Counterstain was performed using Mayer’s hematoxylin.
Electron microscopy. For electron microscopy, mice were 
anesthetized using ketamine/xylazine, and the body circula-
tion was perfused first with 10 ml PBS via a peristaltic pump, 
followed by 40 ml of 2% paraformaldehyde and 2% glutaral-
dehyde in 0.1 M cacodylate buffer, pH 7.2. The tissues were 
removed and post-fixed in reduced 1% osmium tetroxide 
containing 1.5% potassium hexacyanoferrate. Subsequently, 
samples were dehydrated and embedded in epon. 60-nm ul-
trathin sections were cut on an ultramicrotome (UC6; Leica), 
counterstained with uranyl and lead, and imaged on an elec-
tron microscope (Tecnai-12-biotwin; FEI). All vessels were 
analyzed in the area of the section (∼1 mm × 1 mm) and 
imaged for junction integrity (MegaView; Olympus). Fur-
thermore, representative pictures of selected areas were im-
aged on high-resolution pictures with Ditabis plates.
Immunoprecipitation and immunoblotting. For coimmuno-
precipitations, cells were lysed in lysis buffer (20  mM im-
idazole, pH 6.8, 100  mM NaCl, 2  mM CaCl2, 1% Triton 
X-100, 0.04% NaN3, and 1× complete EDTA-free protease 
inhibitors [Roche]). For detection of phospho-tyrosine after 
immunoprecipitation, cells were lysed in lysis buffer contain-
ing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 
1 mM Na3VO4, 1% Triton X-100, 0.04% NaN3, and 1× com-
plete EDTA-free protease inhibitors (Roche). For immuno-
precipitation of proteins from mouse lung lysates, lungs were 
homogenized with an Ultra Turrax (IKA-Werke) in RIPA 
buffer containing 1% NP-40, 1% sodium deoxycholate, 
0.01 M NaPi, 150 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 
and 2× Complete EDTA-free protease inhibitors, followed 
by incubation for 4  h at 4°C. Lysates were centrifuged at 
4°C for 1  h at 20,000  g, and then aliquots were set aside 
for direct blot analysis, and aliquots for immunoprecipitation 
were precleared for 2 h at 4°C with protein A/G–Sephar-
ose and subsequently incubated for 3 h at 4°C with protein 
A/G–Sepharose loaded with the respective antibodies. Im-
munocomplexes were washed five times with lysis buffer and 
analyzed by SDS-PAGE. Total cell or organ lysates or im-
munoprecipitated material was separated by SDS-PAGE and 
transferred to nitrocellulose (Schleicher & Schuell) by wet 
blotting. Blots were analyzed as described previously (Ebnet 
et al., 2000). For detection of phosphorylated tyrosine, milk 
powder in the blocking buffer was replaced by 2% BSA, and 
200 µM Na3VO4 was added.
Rac1 activation assay. HUV ECs were serum starved for 3 h 
before stimulation with vehicle, 6 µM AKB-9778, or 200 ng/
ml COMP-Ang1 for 30 min. Then cells were lysed and a 
G-Lisa Rac1 activation assay was performed according to 
the manufacturer’s protocol (G-LISA Rac1 Activation Assay 
Biochem kit Luminescence format; Cytoskeleton, Inc.). In 
brief, lysates were cleared by centrifugation at 14,000 rpm 
at 4°C for 2 min before protein concentrations were equal-
ized, followed by incubation in a Rac-GTP affinity plate for 
30 min. Next, the levels of GTP-loaded Rac1 proteins were 
detected by Rac1 antibodies and HRP-labeled secondary an-
tibodies, and luminescence was measured in a 96-well plate 
reader (Synergy 2; BioTek).
Pull-downs of Rac1 and Rap1. For GST pull-downs of Rac1 
or Rap1, cells were serum starved for 2–4 h before stimula-
tion with vehicle, AKB-9778, or COMP-Ang1 for 30 min, 
followed by lysis in 50  mM Tris/HCl, pH 7.5, 1% Triton 
X-100, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, and pro-
tease inhibitors for 10 min. Lysates were centrifuged at 14,000 
rpm and 4°C for 10 min and incubated with either Rac1 
Assay Reagent (PAK-PBD-GST Beads; Cytoskeleton, Inc.) 
for a pull-down of Rac1 or Rap1 Assay Reagent (Ral-GDS-
RBD Beads; Merck Millipore) for a pull-down of Rap1 for 
45 min at 4°C in an overhead shaker. Beads were washed four 
times with lysis buffer and, together with aliquots of total ly-
sates, subjected to immunoblot analysis with anti-
bodies for Rac1 or Rap1.
RNA interference. For in vitro RNA interference of Tie-2, the 
siRNA 5′-TCG GTGCT ACTTA ACAAC TTA-3′ (human 
Tie-2; QIA GEN) was used. For RNA-mediated interference 
of Rap1 expression in HUV ECs, the following siRNAs were 
used in combination: 5′-GCA AGACA GTGGT GTAACT-3′ 
(human Rap1A) and 5′-GGA CAAGG ATTTG CATTAG-3′ 
(human Rap1B). As a negative control, siRNA that does 
not target any known mammalian gene was used (5′-UUC 
UCCGA ACGUG UCACGU-3′; QIA GEN). Routinely, 106 
HUV ECs were transfected with 3 or 4 µg siRNA, respec-
tively, using either nucleofection (Amaxa Biosystems) or INT 
ERFERin (Polyplus Transfection) according to the manufac-
turer’s instructions. Cells were analyzed 48 h (Tie-2 siRNA) 
or 72 h (Rap1A/B siRNA) after transfection.
For RNA interference of Tie-2 in vivo, the siRNA 5′-
CAG GAAGG TATGA GTACA AAT-3′ was used. The sequence 
was provided by QIA GEN, tested in vitro, and modified for 
higher stability for in vivo applications by Dharmacon (siSTA 
BLE; GE Healthcare). As a negative control, siRNA that does 
not target any known mammalian gene was used that was 
modified identically (5′-TAG CGACT AAACA CATCAA-3′; 
siSTA BLE; GE Healthcare). Mice were injected i.v. with 60 
µg siRNA using in vivo-jetPEI as transfer reagent (Polyplus 
Transfection) according to the manufacturer’s instructions 
and analyzed 48 h later.
In vivo permeability assay in skin. 1 h before the assay, mice 
were injected subcutaneously with vehicle or AKB-9778 (0.6 
mg per injection). Then, a modified Miles assay for the induc-
tion of vascular permeability in the skin was performed as 
described previously (Mamluk et al., 2005). For each assay, 
four to five 8–12-wk-old female mice were used. Evans blue 
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a 1% solution in PBS), and after 15 min, 50 µl PBS, 100 ng 
murine VEGF165 in 50 µl PBS, or 225 ng histamine in 50 µl 
PBS was injected intradermally into the shaved back skin. 
Then, 30 min later, skin areas were excised and extracted with 
formamide for 5 d, and the concentration of the dye was 
measured at 620 nm with a spectrophotometer (Shimadzu).
In vivo LPS-induced lung permeability assay. 1 h before the 
assay, mice were injected subcutaneously with vehicle or 
AKB-9778 (0.6 mg per injection). To induce lung permeabil-
ity, mice were exposed for 40 min to nebulized LPS (250 µg/
ml Salmonella enteritidis; Sigma-Aldrich) or saline as a con-
trol. 4 h later, mice were i.v. injected with Evans blue and 5 
min (for Cdh5lox/lox/Cdh5iECKO mice) or 15 min (for control/
Tie-2 siRNA–injected mice) later sacrificed, and the lung 
circulation was perfused. Lungs were removed and extracted 
with formamide for 5 d, and the concentration of the dye was 
measured at 620 nm with a spectrophotometer (Shimadzu).
In vivo permeability assay of inner organs. Mice were i.v. in-
jected with Evans blue and 30 min later sacrificed, and the 
body circulation was perfused. Organs of interest were re-
moved and extracted with formamide for 5 d, and the con-
centration of the dye was measured at 620 nm with a 
spectrophotometer (Shimadzu).
In vivo LPS-induced pulmonary inflammation. 1 h before the 
assay, mice were injected subcutaneously with vehicle or AKB-
9778 (0.6 mg per injection). LPS-induced pulmonary inflam-
mation was achieved as previously described (Zarbock et al., 
2009). In brief, LPS from 500 µg/ml Salmonella enteritidis 
(Sigma-Aldrich) was nebulized, and mice were exposed for 
45 min to nebulized LPS or saline as a control. 4 h later, mice 
were sacrificed and the lungs were lavaged with PBS. Leuko-
cyte counts in the bronchoalveolar lavage fluid were analyzed, 
and the numbers of neutrophils were determined by FACS.
In vitro permeability assay. To determine paracellular perme-
ability, 1.5 × 104 or 4 × 104 HUV ECs were seeded on 100 
µg/ml fibronectin–coated Transwell filters (Costar 3413, 0.4-
µm pore size; Corning) and grown to confluence. For stimu-
lation, HUV ECs were starved for 2–4  h with EMB-2 
containing 1% BSA, then preincubated with 200 ng/ml 
COMP-Ang1, 6–12 µM AKB-9778, 100 µg/ml anti–human 
hPTPβ antibody, or control reagents for 30 min, followed by 
stimulation with 1–2 U/ml thrombin (for 30 min) or 200 ng/
ml VEGF165 (for 2 h) parallel to the diffusion of 0.25 mg/ml 
FITC-dextran (250 kD; Sigma-Aldrich) at 37°C and 10% 
CO2. Fluorescence in the lower chamber was measured with 
a fluorimeter (Fluoromax-2; Jobin-Yvon), and monolayer in-
tegrity was confirmed by immunofluorescence staining for 
VE-cadherin after each assay.
In vitro transmigration assay. To analyze transendothelial 
migration of PMNs or T cells across HUV EC monolayers, 
HUV ECs were grown to confluence on fibronectin-coated 
transwell filters (5-µm pore size; Corning) and stimulated 
with 5 nM TNF 15 h before the assay and treated either with 
5 µM AKB-9778 or vehicle. For the assay, 2.5 × 105 human 
PMNs or T cells were allowed to transmigrate for 30 min 
toward the chemokine IL-8 (for PMNs) or SDF-1α (for T 
cells). Transmigrated leukocytes were counted using a CASY 
Cell Counter TT+ (Roche).
Statistical analysis. Datasets were tested for normality (Shap-
iro-Wilk) and equal variance. Statistical significance was ana-
lyzed using the one-way ANO VA test for independent 
samples or Mann-Whitney rank sum test. SigmaPlot 11 soft-
ware was used for this analysis. P-values are indicated by aster-
isks: *, P ≤ 0.05; **, P < 0.01; and ***, P < 0.001. Results are 
shown as means ± SEM. Immunoblot signals were quantified 
using the software Multi-Gauge V3.2 (Fuji). For immunopre-
cipitations, phospho-tyrosine signals were normalized to the 
levels of the precipitated protein.
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